IUCT Oncopole
IUCT Oncopole
Toulouse, France12 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 / Phase 2 | 2026-10-06 | NCT05583617 | |
| A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 | 2026-10-06 | NCT05091424 | |
| Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR) | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bone marrow disorder, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Phase 2 | 2026-09-29 | NCT05768711 | |
| Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Not yet recruiting | Phase 2 | 2026-09-14 | NCT07739459 | |
| A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS | Hemic and Lymphatic Diseases, bone marrow disorder, hematologic disorder, myelodysplastic syndrome | Active, not recruiting | Phase 3 | 2026-09-11 | NCT03223961 | |
| Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Not yet recruiting | Phase 2 | 2026-09-10 | NCT07814001 | |
| Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes | Untreated Myelodysplastic Syndrome | Active, not recruiting | Phase 1 / Phase 2 | 2026-08-11 | NCT05782127 | |
| Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse | Diffuse Large B-cell Lymphoma Refractory; Refractory High Grade B-Cell Lymphoma; Refractory Primary Mediastinal Large B-Cell Lymphoma; Refractory Transformed B-cell Non-Hodgkin Lymphoma | Recruiting | Phase 2 | 2026-06-04 | NCT06271057 | |
| ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable) | metastatic prostate carcinoma | Recruiting | Phase 3 | 2026-04-28 | NCT04916613 | |
| Venetoclax in Patients With MDS or AML in Relapse After AHSCT | acute myeloid leukemia, myelodysplastic syndrome | Active, not recruiting | Phase 1 / Phase 2 | 2026-03-12 | NCT05226455 | |
| Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, bone disorder, bone sarcoma, connective tissue neoplasm, musculoskeletal system disorder, neoplasm, osteosarcoma, sarcoma | Recruiting | Phase 2 | 2026-02-17 | NCT04698785 | |
| Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas | Ewing sarcoma, Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, connective tissue neoplasm, histiocytoma, neoplasm, osteosarcoma, sarcoma, undifferentiated pleomorphic sarcoma | Recruiting | Phase 2 | 2025-10-07 | NCT05182164 |